Adrenocortical carcinoma natural history: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 15: Line 15:
==Prognosis==  
==Prognosis==  
Adrenocortical carcinoma, generally, carries a poor prognosis.<ref name="allolio">{{cite journal | author = Allolio B, Fassnacht M | title = Clinical review: Adrenocortical carcinoma: clinical update. | journal = J Clin Endocrinol Metab | volume = 91 | issue = 6 | pages = 2027-37 | year = 2006 | id = PMID 16551738}} [http://jcem.endojournals.org/cgi/content/full/91/6/2027 Free Full Text].</ref>
Adrenocortical carcinoma, generally, carries a poor prognosis.<ref name="allolio">{{cite journal | author = Allolio B, Fassnacht M | title = Clinical review: Adrenocortical carcinoma: clinical update. | journal = J Clin Endocrinol Metab | volume = 91 | issue = 6 | pages = 2027-37 | year = 2006 | id = PMID 16551738}} [http://jcem.endojournals.org/cgi/content/full/91/6/2027 Free Full Text].</ref>
The five-year disease-free survival rate for a complete resection of a [[Cancer staging|stage]] I-III is approximately 30%.<ref name="allolio" />
The five-year disease-free survival rate for a complete resection of a [[Cancer staging|stage]] I-III is approximately 30%.<ref name="allolio" />


The most important prognostic factors are:
The most important prognostic factors are:
* Age of the patient
* Age of the patient (243).
* Stage of the tumor
* Stage of the tumor (243, 244)
* Mitotic activity
* Mitotic activity (245).
* Venous invasion
* Venous invasion
* Weight more than 50 Kg
* Weight more than 50 Kg
* Diameter more than 6.5 cm
* Diameter more than 6.5 cm
* Cortisol production  as an adverse prognostic factor (12, 85, 244).
* Ki-67/MIB1 labeling index (antigen identified by monoclonal antibody Ki-67)
* Ki-67/MIB1 labeling index (antigen identified by monoclonal antibody Ki-67)
* Survival ranges from a few months to several years. (242)  
* Survival ranges from a few months to several years. (242)  
* In the Michigan  Endocrine Oncology Repository, roughly 5% of all  patients diagnosed with ACC will have a disease course of  _10 years (T.E., unpublished results).  Although this may be caused by a referral bias, there is an emerging notion of an ACC population with exceptionally long survival.  Despite these variations in survival, prognostic factors  have not been definitively researched. Naturally, age at  diagnosis is correlated with decreased overall survival  (243).  However, whether this is true for tumor-free survival  remains unclear. Tumor characteristics of malignancy  and velocity of tumor growth are usually related to  a decreased survival. Tumor extent (eg, stage), specifically  the presence of distant metastasis and number of organs  involved in metastatic disease, confers a worse prognosis  (243, 244).  High tumor grade (_20 mitoses per HPF) is  also an unfavorable prognostic indicator (245). Although  older studies did not show any differences in prognoses for  patients harboring different hormone secretion subtypes  of ACC, some recent studies identified cortisol production  as an adverse prognostic factor (12, 85, 244).


==References==
==References==

Revision as of 19:07, 21 September 2017

Adrenocortical carcinoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Adrenocortical carcinoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Staging

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

MRI

CT

Ultrasound

Other Imaging Studies

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Radiation Therapy

Primary prevention

Secondary prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Study

Case #1

Adrenocortical carcinoma natural history On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Adrenocortical carcinoma natural history

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Adrenocortical carcinoma natural history

CDC on Adrenocortical carcinoma natural history

Adrenocortical carcinoma natural history in the news

Blogs on Adrenocortical carcinoma natural history

Hospitals Treating Adrenocortical carcinoma

Risk calculators and risk factors for Adrenocortical carcinoma natural history

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Raviteja Guddeti, M.B.B.S. [2] Ahmad Al Maradni, M.D. [3]

Overview

Prognosis is generally poor, and the 5-year survival rate of patients with adrenocortical carcinoma stage I-III is approximately 30%. Complication may include metastasis, Conn syndrom and Cushing syndrom

Complications

The following are the complications of Adrenocortical carcinoma:

Prognosis

Adrenocortical carcinoma, generally, carries a poor prognosis.[1]

The five-year disease-free survival rate for a complete resection of a stage I-III is approximately 30%.[1]

The most important prognostic factors are:

  • Age of the patient (243).
  • Stage of the tumor (243, 244)
  • Mitotic activity (245).
  • Venous invasion
  • Weight more than 50 Kg
  • Diameter more than 6.5 cm
  • Cortisol production as an adverse prognostic factor (12, 85, 244).
  • Ki-67/MIB1 labeling index (antigen identified by monoclonal antibody Ki-67)
  • Survival ranges from a few months to several years. (242)

References

  1. 1.0 1.1 Allolio B, Fassnacht M (2006). "Clinical review: Adrenocortical carcinoma: clinical update". J Clin Endocrinol Metab. 91 (6): 2027–37. PMID 16551738. Free Full Text.

Template:WikiDoc Sources